Aldosterone breakthrough does not alter central hemodynamics.

ABSTRACT:

Introduction

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are widely used in congestive heart failure and chronic kidney disease, but up to 40% of patients will experience aldosterone breakthrough, with aldosterone levels rising above pre-treatment levels after 6-12 months of renin-angiotensin-aldosterone system blockade. Aldosterone breakthrough has been associated with worsening congestive heart failure and chronic kidney disease, yet the pathophysiology remains unclear. Breakthrough has not been associated with elevated peripheral blood pressure, but no studies have assessed its effect on central blood pressure.

Methods

Nineteen subjects with well-controlled peripheral blood pressure on stable doses of angiotensin-converting enzyme inhibitor/

SUBMITTER: Beenken A 

PROVIDER: S-EPMC5843861 | biostudies-literature | 2017 Oct-Dec

REPOSITORIES: biostudies-literature